Core Insights - Xiangsheng Medical (688358) has seen its stock price increase by 8.12% this week, closing at 35.27 yuan as of October 24, 2025, with a market capitalization of 3.955 billion yuan [1] Financial Performance - For Q3 2025, Xiangsheng Medical reported revenue of 107 million yuan, a year-on-year decrease of 6.68%. However, net profit attributable to shareholders increased by 41.95% to 24.224 million yuan. The net profit after excluding non-recurring items was 23.141 million yuan, reflecting a 53.63% increase [2][4] - Cumulatively, for the first three quarters, the company generated revenue of 343 million yuan, down 5.27% year-on-year, while net profit attributable to shareholders decreased by 4.56% to 93.921 million yuan. The total profit increased by 63.21%, primarily due to changes in foreign exchange gains and losses [2] Shareholder Changes - As of September 30, 2025, the number of shareholders for Xiangsheng Medical was 6,167, a reduction of 464 shareholders or 7.0% compared to June 30, 2025. The average number of shares held per shareholder increased from 16,900 shares to 18,200 shares, with an average holding value of 598,200 yuan [1][4] Company Announcements - The board of directors approved several resolutions, including the adjustment of the grant price for the 2024 restricted stock incentive plan from 13.50 yuan to 12.50 yuan per share. Additionally, 26 incentive targets were confirmed to be eligible for 100,860 shares of restricted stock. The company also canceled 97,790 shares of unvested restricted stock and set the grant date for the 2025 restricted stock incentive plan on October 23, 2025, awarding 160,000 shares at a price of 16.50 yuan per share [3]

Core Points - Xiangsheng Medical (688358) closed at 35.27 yuan on October 24, 2025, up 4.75% from the previous trading day, with a total market capitalization of 3.955 billion yuan [1] - The stock opened at 33.65 yuan, reached a high of 36.26 yuan, and a low of 33.65 yuan, with a trading volume of 136 million yuan and a turnover rate of 3.43% [1] Summary of Relevant Sections - The company announced the first vesting period of its 2024 restricted stock incentive plan, with 100,860 shares to be vested, sourced from repurchased A-shares [1] - The initial grant date is set for October 22, 2024, with the vesting period from October 23, 2025, to October 22, 2026 [1] - The company achieved a gross profit of 276.3152 million yuan in 2024, meeting the performance assessment trigger value, resulting in a vesting ratio of 92.11% at the company level [1] - Out of 30 initial grantees, 26 met the vesting conditions, while 3 lost their rights due to resignation and 1 due to failing the assessment [1] - The adjusted grant price is set at 12.50 yuan per share, and the board's compensation and assessment committee, along with the law firm, confirmed compliance with relevant regulations [1]

Core Insights - The medical device sector experienced a slight increase of 0.37% on October 24, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Medical Device Sector Performance - Top gainers included: - Mai Lande (688273) with a closing price of 41.92, up 6.31%, trading volume of 29,300 hands, and a transaction value of 121 million yuan [1] - Xiangyu Medical (688626) at 53.21, up 6.10%, with a trading volume of 41,100 hands and a transaction value of 216 million yuan [1] - Xiangsheng Medical (688358) at 35.27, up 4.75%, with a trading volume of 38,400 hands and a transaction value of 136 million yuan [1] - Other notable gainers included: - Aohua Endoscopy (688212) at 50.59, up 4.74%, with a transaction value of 225 million yuan [1] - Weisi Medical (688580) at 49.10, up 4.71%, with a transaction value of approximately 99.8 million yuan [1] Decliners in Medical Device Sector - Notable decliners included: - Chenguang Medical (920300) at 17.51, down 8.80%, with a trading volume of 124,000 hands [2] - Toukeng Life (300642) at 22.95, down 5.40%, with a trading volume of 175,700 hands [2] - Haitai New Light (688677) at 48.50, down 5.05%, with a trading volume of 38,800 hands [2] - Other significant decliners included: - Sino Medical (688108) at 28.00, down 4.73%, with a trading volume of 263,700 hands [2] - Tianchen Medical (688013) at 55.66, down 3.98%, with a trading volume of 19,200 hands [2] Capital Flow in Medical Device Sector - The medical device sector saw a net outflow of 654 million yuan from major funds, while retail investors contributed a net inflow of 455 million yuan [2]

Core Points - The company announced the approval of a restricted stock incentive plan for 17 individuals, with a grant date set for October 23, 2025 [2] - The grant price for the restricted stock is determined at 16.50 yuan per share, totaling 160,000 shares to be awarded [2] Company Actions - The company held its 16th meeting of the third board of directors and the 6th meeting of the remuneration and assessment committee on October 23, 2025 [2] - The decision to grant restricted stock is part of the company's strategy to incentivize key personnel [2]

Group 1 - The core point of the article is that Xiangsheng Medical (SH 688358) announced the convening of its 16th board meeting on October 23, 2025, to review the proposal for adjusting the grant price of the 2024 restricted stock incentive plan [1] - For the year 2024, Xiangsheng Medical's revenue composition is heavily weighted towards the medical device industry, accounting for 99.88%, while other businesses contribute only 0.12% [1] - As of the report, Xiangsheng Medical has a market capitalization of 3.8 billion yuan [1]

无锡祥生医疗科技股份有限公司 董事会薪酬与考核委员会 关于公司 2025 年限制性股票激励计划授予激励对象名单的 核查意见（截至授予日） 无锡祥生医疗科技股份有限公司（以下简称"公司"）董事会薪酬与考核委员 会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、 《科创板上市公司自律监管指南第 4 号——股权激励信息披露》（以下简称"《监 管指南》"）等相关法律、法规及规范性文件和《无锡祥生医疗科技股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，对公司《2025 年限制性股票 激励计划》（以下简称"本次激励计划"）授予激励对象名单（截至授予日）进行 审核，发表核查意见如下： 1、公司本次激励计划授予的激励对象均不存在《管理办法》第八条规定的 不得成为激励对象的情形： （1）最近 12 个月内被证券交易所认定为不适当人选； （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-039 无锡祥生医疗科技股份有限公司 关于 2024 年限制性股票激励计划首次授予部分 第一个归属期符合归属条件的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次股权激励计划批准及实施情况 （2）授予数量：本激励计划拟向激励对象授予 593,000 股限制性股票，约 占本激励计划草案公告时公司股本总额 112,124,537 股的 0.53%。其中，首次授 予 475,500 股，约占本激励计划草案公告时公司总股本 112,124,537 股的 0.42%， 首次授予部分占本次授予权益总额的 80.19%；预留 117,500 股，约占本激励计划 草案公告时公司总股本 112,124,537 股的 0.10%，预留部分占本次授予权益总额 的 19.81%。 （3）授予价格（调整后）：12.50 元/股，即满足授予条件和归属条件后，激 限制性股票拟归属数量：100,860 股 归属股票来源：无锡祥生医疗科技股份有限公司（以下简称"公司 ...

无锡祥生医疗科技股份有限公司 2025 年股权激励计划授予激励对象名单 | 激励对象职务 | 激励对象 | 获授限制性股票数 | 占授予限制性股票 | 占本激励计 | | --- | --- | --- | --- | --- | | 人数 | | 量(股) | 总数比例 | 划公告日股 本总额比例 | | 一、董事、高级管理人员、核心技术人员 | | | | | | / | / | / | / | / | | 二、其他激励对象 | | | | | | 董事会认为需要激励的人员 （17 人） | | 160,000 | 100% | 0.14% | | 合计 | | 160,000 | 100% | 0.14% | 2025 年 10 月 23 日 注：1、公司全部有效期内的股权激励计划所涉及的标的股票总数累计未超过本激励计 划草案公告时公司股本总额的 20.00%。本激励计划中任何一名激励对象通过全部在有效期 内的股权激励计划获授的限制性股票数量累计均未超过本激励计划草案公告时公司股本总 额的 1.00%。 （截至授予日） 无锡祥生医疗科技股份有限公司董事会 一、限制性股票激励计划的分配情况表 2、参与本激 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-037 无锡祥生医疗科技股份有限公司 关于调整 2024 年限制性股票激励计划授予价格的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 无锡祥生医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 23 日 召开的第三届董事会第十六次会议、第三届董事会薪酬与考核委员会第六次会议， 审议通过了《关于调整 2024 年限制性股票激励计划授予价格的议案》，同意公司 根据《无锡祥生医疗科技股份有限公司 2024 年限制性股票激励计划》（以下简称 "本激励计划"）的有关规定，对公司 2024 年限制性股票激励计划授予价格进行 调整，由 13.50 元/股调整为 12.50 元/股。现将有关事项说明如下： 一、本激励计划已履行的决策程序和信息披露情况 1、2024 年 9 月 27 日，公司召开第三届董事会第八次会议，会议审议通过 了《关于公司<2024 年限制性股票激励计划（草案）>及其摘要的议案》、《关于 公司<2024 年限制性股票激励计划实施考核 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-038 无锡祥生医疗科技股份有限公司 同日，公司召开第三届监事会第七次会议，审议通过了《关于公司<2024 年 限制性股票激励计划（草案）>及其摘要的议案》、《关于公司<2024 年限制性股 票激励计划实施考核管理办法>的议案》以及《关于核实公司<2024 年限制性股 票激励计划激励对象名单>的议案》，公司监事会对本激励计划的相关事项进行核 实并出具了相关核查意见。 关于作废处理 2024 年限制性股票激励计划 部分限制性股票的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 无锡祥生医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 23 日 召开的第三届董事会第十六次会议、第三届董事会薪酬与考核委员会第六次会 议，审议通过了《关于作废处理 2024 年限制性股票激励计划部分限制性股票的 议案》。根据公司《2024 年限制性股票激励计划》（以下简称"《激励计划》"或"本 激励计划"）、《2024 年限制性股票激励计划实施考核管理办法》（以下 ...